Clincosm LogoSign in Get a demo

Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group

Sponsor
Bukwang Pharmaceutical (Industry)
Overall Status
Terminated
CT.gov ID
NCT00313261
Collaborator
(none)
7
Locations
20.1
Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and antiviral activity of clevudine 30 mg QD for treatment of longer period (24 weeks) in patients chronically infected with HBV.

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of L-FMAU (Clevudine) in Chronic Hepatitis B Patients of L-FMAU-201 Placebo Group
Study Start Date :
Jun 1, 2003
Study Completion Date :
Feb 1, 2005

Outcome Measures

Primary Outcome Measures

  1. Efficacy: Change from baseline in HBV DNA (log10) []

  2. Safety: Laboratory tests, Adverse Events, Vital Signs, ECG []

Secondary Outcome Measures

  1. Efficacy []

  2. Proportion of patients with HBV DNA below the assay Limit of Detection (4,700 copies/mL by Digene Hybrid Capture II) []

  3. Biochemical improvement (ALT normalization) []

  4. Serology Proportion of patients with HBeAg loss Seroconversion rate (HBeAg loss and anti-HBe gain) []

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Patients who received placebo in L-FMAU-201 study

  2. Female of childbearing potential with a negative serum (beta-HCG) pregnancy test within 14 days of starting therapy.

  3. Patients who were able to give written informed consent prior to study start and to comply with the study requirements.

  4. Patients who met the following criteria after completion of the Week 48 visit were to have additional follow-up visits at Weeks 54 and 60:

1)had received no additional therapy since completion of 24-week treatment of clevudine and 2)experienced a >= 1 log10 decrease from baseline in HBV DNA at Week 48

Exclusion Criteria:

  1. Patient with HBeAg seroconverted to anti-HBe at the last 2 consecutive visits (one month apart) in L-FMAU-201 study.

  2. Patient who was currently receiving antiviral, immunomodulatory or corticosteroid therapy.

  3. Patient who was treated with lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for HBV infection after cessation of treatment in L-FMAU-201 study.

  4. Patient who had a history of ascites, variceal hemorrhage or hepatic encephalopathy.

  5. Patient who was co-infected with HCV, HDV or HIV.

  6. Patient with clinical evidence of cirrhosis or hepatocellular carcinoma (®-Fetoprotein)Evaluation was based on alpha-fetoprotein primarily. If alpha-fetoprotein level was suggestive of cirrhosis or hepatocellular carcinoma, confirmation was made with ultrasonography etc.

  7. Patient who was pregnant or breast-feeding.

  8. Patient who was unwilling to use an "effective" method of contraception during treatment period and for up to 3 months after cessation of therapy. For males, condoms should be used. Females must be surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal or using at least a medically acceptable barrier method of contraception (i.e., IUD, barrier methods with supermicide or abstinence)

  9. Patient who had a clinically relevant history of abuse of alcohol or drugs.

  10. Patient who had a significant gastrointestinal, renal, hepatic (decompensated), bronchopulmonary, neurological, cardiovascular, oncologic or allergic disease.

  11. Patient who had creatinine clearance less than 60mL/min as estimated by the following formula:

(140-age in years) (body weight [kg])/(72) (serum creatinine [mg/dL]) [Note: multiply estimates by 0.85 for women]

Contacts and Locations

Locations

Site City State Country Postal Code
1 Korea University Guro Hospital Guro-dong Guro-ku, Seoul Korea, Republic of
2 Seoul National University Yeongeon-dong Jongno-Gu, Seoul Korea, Republic of
3 Yongdong Severance Hospital Dogok-dong Kangnam-Gu, Seoul Korea, Republic of
4 Samsung Medical Center Ilwon-dong Kangnam-Gu, Seoul Korea, Republic of
5 Asan Medical Center Pungnab2-dong Songpa-Gu, Seoul Korea, Republic of
6 Ewha Womans University Hospital Mok-dong Yangchon-Gu, Seoul Korea, Republic of
7 St. Mary's Hospital Youido Yougdungpo-Gu, Seoul Korea, Republic of

Sponsors and Collaborators

  • Bukwang Pharmaceutical

Investigators

  • Principal Investigator: Hyo Suk Lee, M.D., Ph.D., Seoul National University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00313261
Other Study ID Numbers:
  • L-FMAU-203
First Posted:
Apr 12, 2006
Last Update Posted:
Oct 17, 2012
Last Verified:
Oct 1, 2012
Additional relevant MeSH terms:
Hepatitis B
Hepatitis
Clevudine

Study Results

No Results Posted as of Oct 17, 2012